Task D8: Nonclinical Services for Interventional Agents against SARS-CoV-2

任务 D8：针对 SARS-CoV-2 干预药物的非临床服务

• 批准号: 10683809
• 负责人: WILLIAM JOHNSON
• 金额: $ 188.35万
• 依托单位: IIT RESEARCH INSTITUTE
• 依托单位国家: 美国
• 财政年份: 2018
• 资助国家: 美国
• 起止时间: 2018-05-01 至 2025-04-30
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10683809
• 关键词: 2019-nCoV; COVID-19 therapeutics; Chemistry; Communicable Diseases; Development; Development Plans; Drug Kinetics; Evaluation; In Vitro; Interventional Agent Development; Lead; Microbiology; Safety; Services; Therapeutic; Toxicology; Toxin; in vivo; pathogen; pre-clinical; product development; programs; service intervention; therapeutic development

The Non-clinical Services for Development of Interventional Agents for Infectious Diseases program provides services to facilitate preclinical product development of promising therapeutics for infectious disease-causing pathogens and/or toxins. Services include: preclinical product development planning and evaluation; lead identification and development; chemistry and GMP manufacturing; in vitro and in vivo preclinical microbiological, safety, toxicology and pharmacokinetics.

传染病干预药物开发非临床服务项目提供服务，以促进有前景的传染病病原体和/或毒素治疗药物的临床前产品开发。服务包括：临床前产品开发计划和评价;先导化合物鉴定和开发;化学和GMP生产;体外和体内临床前微生物、安全性、毒理学和药代动力学。